RT Journal Article
T1 Respiratory Syncytial Virus Vaccination Recommendations for Adults Aged 60 Years and Older: The NeumoExperts Prevention Group Position Paper
A1 Redondo, Esther
A1 Rivero Calle, Irene
A1 Martinón Torres, Federico
K1 Respiratory syncytial virus
K1 RSV
K1 Adult patients
K1 Vaccination
K1 Recommendations
K1 Preventive measures
K1 High-risk populations
K1 Chronic obstructive pulmonary disease
AB Respiratory syncytial virus (RSV) is a major cause of respiratory tract infections in adults, particularly older adults and those with underlying medical conditions. Vaccination has emerged as a potential key strategy to prevent RSV-related morbidity and mortality. This Neumoexperts Prevention (NEP) Group scientific paper aims to provide an evidence-based positioning and RSV vaccination recommendations for adult patients. We review the current literature on RSV burden and vaccine development and availability, emphasising the importance of vaccination in the adult population. According to our interpretation of the data, RSV vaccines should be part of the adult immunisation programme, and an age-based strategy should be preferred over targeting high-risk groups. The effectiveness and efficiency of this practice will depend on the duration of protection and the need for annual or more spaced doses. Our recommendations should help healthcare professionals formulate guidelines and implement effective vaccination programmes for adult patients at risk of RSV infection now that specific vaccines are available.
PB Elsevier
SN 0300-2896
YR 2024
FD 2024
LK http://hdl.handle.net/10347/33844
UL http://hdl.handle.net/10347/33844
LA eng
NO Archivos de Bronconeumología Volume 60, Issue 3, March 2024, Pages 161-170
NO This work was supported by consorcio Centro de Investigacion Biomédica en Red de Enfermedades Respiratorias (CB21/06/00103; FM-T), DIAVIR (Instituto de Salud Carlos III (ISCIII)/DTS19/00049/Cofinanciado FEDER; Proyecto de Desarrollo Tecnológico en Salud), Resvi-Omics (Instituto de Salud Carlos III (ISCIII)/PI19/01039/Cofinanciado FEDER), BI-BACVIR (PRIS-3; Agencia de Conocimiento en Salud (ACIS)—Servicio Gallego de Salud (SERGAS)—Xunta de Galicia; Spain), Programa Traslacional COVID-19 (ACIS—Servicio Gallego de Salud (SERGAS)—XUNTA de Galicia; Spain) and Axencia Galega de Innovacion (GAIN; IN607B 2020/08—XUNTA de Galicia; Spain); and ReSVinext (Instituto de Salud Carlos III (ISCIII)/PI16/01569/Cofinanciado FEDER), Enterogen (Instituto de Salud Carlos III (ISCIII)/PI19/01090/Cofinanciado FEDER), OMI-COVI-VAC (PI22/00406/Cofinanced European Regional Development Fund, Grupos de Referencia Competitiva (IIN607A2021/05) and Axencia Galega de Innovación (GAIN; IN845D 2020/23—Xunta de Galicia; Spain).
DS Minerva
RD 4 may 2026